Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database

被引:2
|
作者
Sportiello, Liberata [1 ,2 ]
Di Napoli, Raffaella [1 ,2 ]
Balzano, Nunzia [1 ,2 ]
Mascolo, Annamaria [1 ,2 ]
Ruggiero, Rosanna [1 ,2 ]
Di Costanzo, Luigi [2 ]
Monaco, Davida [1 ,2 ]
Maniscalco, Giorgia Teresa [3 ,4 ,5 ]
Capuano, Annalisa [1 ,2 ]
机构
[1] Univ Campania Luigi Vanvitelli, Campania Reg Ctr Pharmacovigilance & Pharmacoepide, I-80138 Naples, Italy
[2] Univ Campania Luigi Vanvitelli, Dept Expt Med, I-80138 Naples, Italy
[3] A Cardarelli Hosp, Multiple Sclerosis Reg Ctr, I-80131 Naples, Italy
[4] A Cardarelli Hosp, Neurol Clin, I-80131 Naples, Italy
[5] A Cardarelli Hosp, Stroke Unit, I-80131 Naples, Italy
关键词
disease-modifying therapies; pregnancy; breastfeeding; women; adverse drug reaction; safety; database; spontaneous reporting; DELIVERY; ISSUES;
D O I
10.3390/ph16111566
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
(1) Background: The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS). (2) Methods: Individual case safety reports (ICSRs) were retrieved from the European spontaneous reporting system database (EudraVigilance). The reporting odds ratios (RORs) were computed to compare the reporting probability of events between natalizumab, alemtuzumab and ocrelizumab vs. glatiramer. (3) Results: A total of 1236 ICSRs reporting at least one DMT as a suspected drug were selected. More adverse drug reactions (ADRs) unrelated to pregnancy and breastfeeding (n = 1171; 32.6%) were reported than ADRs specific to pregnancy and breastfeeding (n = 1093; 30.4%). The most frequently reported unrelated ADR was MS relapse. Alemtuzumab and natalizumab seem to have a lower reporting probability of MS relapse compared to glatiramer (ROR 0.17, 95% CI 0.07-0.45 and ROR 0.34, 95% CI 0.20-0.57). Among pregnancy- and breastfeeding-related ADRs, the first most reported event was spontaneous abortion (n = 321; 8.9%). Natalizumab and ocrelizumab were associated with a higher reporting probability of spontaneous abortion compared to glatiramer (ROR 2.22, 95% CI 1.58-3.12; ROR 2.18, 95% CI 1.34-3.54, respectively), while alemtuzumab had a lower reporting frequency (ROR 0.32, 95% CI 0.17-0.60). (4) Conclusions: This study did not suggest any strong or new insights for DMTs in this special subpopulation. However, further studies need to be performed.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University
    Vural, Ezgi
    Engin, Esin
    Sunter, Gulin
    Agan, Kadriye
    Gunal, Dilek
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023, 53 (03) : 771 - 779
  • [42] Association between prenatal exposure to antidepressants and neonatal morbidity: An analysis of real-world data from a nationwide claims database in Japan
    Fujioka, Izumi
    Ohtsu, Hiroshi
    Yonemoto, Naohiro
    Sase, Kazuhiro
    Murashima, Atsuko
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 310 : 60 - 67
  • [43] Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
    Hernandez, Luis
    Guo, Shien
    Toro-Diaz, Hector
    Carroll, Stuart
    Farooq, Syed Feisal Syed
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 228 - 238
  • [44] Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database
    Pinter, Andreas
    Schulte, Marcus
    Kossack, Nils
    Pignot, Marc
    Schultze, Michael
    Feldhus, Andrea
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 207 - 220
  • [45] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial
    Vermersch, Patrick
    Oreja-Guevara, Celia
    Siva, Aksel
    Van Wijmeersch, Bart
    Wiendl, Heinz
    Wuerfel, Jens
    Buffels, Regine
    Kadner, Karen
    Kuenzel, Thomas
    Comi, Giancarlo
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (03) : 790 - 801
  • [46] Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)
    Titievsky, Lina
    Schuster, Tilman
    Wang, Ronnie
    Younus, Muhammad
    Palladino, Andrew
    Quazi, Kabir
    Wajnrajch, Michael P.
    Hernandez, Betina
    Becker, Pamela S.
    Weinreb, Neal J.
    Chambers, Christina
    Mansfield, Roy
    Taylor, Louise
    Tseng, Li-Jung
    Kaplan, Paige
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [47] Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)
    Lina Titievsky
    Tilman Schuster
    Ronnie Wang
    Muhammad Younus
    Andrew Palladino
    Kabir Quazi
    Michael P. Wajnrajch
    Betina Hernandez
    Pamela S. Becker
    Neal J. Weinreb
    Christina Chambers
    Roy Mansfield
    Louise Taylor
    Li-Jung Tseng
    Paige Kaplan
    Orphanet Journal of Rare Diseases, 17
  • [48] Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023
    Li, Xiangyu
    Yang, Fang
    Zhou, Fuqun
    Zhu, Shenghong
    Yuan, Lingjing
    Ma, Li
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [49] Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data
    Tang, Jian
    Li, Qing
    Huang, Zhaopeng
    Shi, Lishuo
    Guo, Qin
    Li, Miao
    Gao, Xiang
    Chao, Kang
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (05) : 749 - 755
  • [50] Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
    Wang, T.
    Wang, F.
    Gou, Z.
    Tang, H.
    Li, C.
    Shi, L.
    Zhai, S.
    DIABETES OBESITY & METABOLISM, 2015, 17 (01) : 32 - 41